참고문헌
- Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005;241:27-39
- The Information Committee of the Korean Gasric Cancer Association. 2004 Nationwide Gastric Cancer Report in Korea. J Korean Gastric Cancer Assoc 2007;7:47-54
- Stokkel MP, ten Broek FW, Hordijk GJ, Koole R, van Rijk PP. Preoperative evaluation of patients with primary head and neck cancer using dual-head F-18 fluorodeoxyglucose positron emission tomography. Ann Surg 2000;231:229-34 https://doi.org/10.1097/00000658-200002000-00012
- Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, et al. Preoperative staging of non-small-cell lung cancer with positron emission tomography. N Engl J Med 2000;343:254-61 https://doi.org/10.1056/NEJM200007273430404
- Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Din Oncol 2000;18:3202-10
- Flamen P. Positron emission tomography in colorectal cancer. Best Pract Res Clin Gastroenterol 2002;16:237-51 https://doi.org/10.1053/bega.2001.0283
- Yeung HW, Macapinlac H, Karpeh M, Finn RD, Larson SM. Accuracy of FDG-PET in gastric gancer. Preliminary experience. Clin Positron Imaging 1998;1:213-21 https://doi.org/10.1016/S1095-0397(98)00018-1
-
Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of
$^{18}F$ -2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 2004;28:247-53 https://doi.org/10.1007/s00268-003-7191-5 - Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003;30:288-95 https://doi.org/10.1007/s00259-002-1029-5
- Chen J, Cheong JH, Yun MJ, Kim J, Lim JS, Hyung WJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 2005;103:2383-90 https://doi.org/10.1002/cncr.21074
- Koga H, Sasaki M, Kuwahara Y, Hiraka K, Nakagawa M, Abe K, et al. An analysis of the physiological FDG uptake pattern in the stomach. Ann Nucl Med 2003; 17:733-8 https://doi.org/10.1007/BF02984984
- Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer 2006;9: 192-6 https://doi.org/10.1007/s10120-006-0374-7
-
Shoda H, Kakugawa Y, Saito D, Kozu T, Terauchi T, Daisaki H, et al. Evaluation of
$^{18}F$ -2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. Br J Cancer 2007;97:1493-8 https://doi.org/10.1038/sj.bjc.6604062 - Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, et al. Expression of glucose transporter-l in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 2001;92:634-41 https://doi.org/10.1002/1097-0142(20010801)92:3<634::AID-CNCR1364>3.0.CO;2-X
- Yamamoto T, Seino Y, Fukmnoto H, Koh G, Yano H, Inagaki N, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990;170:223-30 https://doi.org/10.1016/0006-291X(90)91263-R
- Younes M, Lechago LV, Lechago J. Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Din Cancer Res 1996;2:1151-4
- Uchino S, Tsuda H, Maruyama K, Kinoshita T, Sasako M, Saito T, et al. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 1993;72:3179-84 https://doi.org/10.1002/1097-0142(19931201)72:11<3179::AID-CNCR2820721108>3.0.CO;2-#
- Wang YL, Sheu BS, Yang HB, Lin PW, Chang YC. Overexpression of c-erb-B2 proteins in tumor and non-tumor parts of gastric adenocarcinoma--emphasis on its relation to H. pylori infection and clinicohistological characteristics. Hepatogastroenterology 2002;49: 1172-6
- Lazar D, Tahan S, Ardeleanu C, Simionescu C, Sporea I, Cornianu M, et al. Immunohistochemical expression of the cyclooxygenase-2 (COX-2) in gastric cancer. The correlations with the tumor angiogenesis and patients' survival. Rom J Morphol Embryol 2008;49:371-9
- Garcia I, Vizoso F, Martin A, Sanz L, Abdel-Lab O, Raigoso P, et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003;10:234-41 https://doi.org/10.1245/ASO.2003.05.010
- Matsubara J, Yamada Y, Nakajima TE, Kato K, Hamaguchi T, Shirao K, et al. Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology 2008;74:76-83 https://doi.org/10.1158/1078-0432.CCR-07-1898
- Manuel Del Casar J, Vizoso FJ, Abdel-Laa O, Sanz L, Martin A, Daniela Corte M, et al. Prognostic value of cytosolyc cathepsin D content in resectable gastric cancer. J Surg Oncol 2004;86: 16-21 https://doi.org/10.1002/jso.20041
- Chen L, Li X, Wang GL, Wang Y, Zhu YY, Zhu J. Clinicopathological significance of overexpression of TSPANI, Ki67 and CD34 in gastric carcinoma Tumori 2008;94:531-8 https://doi.org/10.1177/030089160809400415
- Ishida M, Gomyo Y, Tatebe S, Ohfuji S, Ito H. Apoptosis in human gastric mucosa, chronic gastritis, dysplasia and carcinoma: analysis by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labelling. Virchows Arch 1996;428:229-35 https://doi.org/10.1007/BF00196695
- Cho JH, Kim WH. Altered topographic expression of p2IWAF1/CIP1/SDI1, bcl2 and p53 during gastric carcinogenesis. Pathol Res Pract 1998;194:309-17 https://doi.org/10.1016/S0344-0338(98)80054-X
- Gomyo Y, Osaki M, Kaibara N, Ito H. Numerical aberration and point mutation of p53 gene in human gastric intestinal metaplasia and well-differentiated adenocarcinoma: analysis by fluorescence in situ hybridization (FISH) and PCR-SSCP. Int J Cancer 1996;66:594-9 https://doi.org/10.1002/(SICI)1097-0215(19960529)66:5<594::AID-IJC2>3.0.CO;2-O
- Triantafillou NG, Grosman IM, Verma RS. Genomania of p53 protein in gastric cancer. J Clin Gastroenterol 1996;22:170-3 https://doi.org/10.1097/00004836-199604000-00003
- Feng CW, Wang LD, Jiao LH, Liu B, Zheng S, Xie XJ. Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features. BMC Cancer 2002;2:8. https://doi.org/10.1186/1471-2407-2-8
- Ishii HH, Gobe GC, Pan W, Yoneyama J, Ebihara Y. Apoptosis and cell proliferation in the development of gastric carcinomas: associations with c-myc and p53 protein expression. J Gastroenterol Hepatol 2002;17:966-72 https://doi.org/10.1046/j.1440-1746.2002.02805.x
- Triantaifyllou K, Kitsanta P, Kararnanolis DG, Kittas C, Ladas SD. Epithelial cell turnover, p53 and bcl-2 protein expression during oncogenesis of early and advanced gastric cancer in a Western population. Dig liver Dis 2008;40:39-45 https://doi.org/10.1016/j.dld.2007.09.010
- Lee KE, Lee HJ, Kim YH, Yu HJ, Yang HI<, Kim WH, et al. Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol 2003;33:173-9 https://doi.org/10.1093/jjco/hyg039
- De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 2002;29:525-9 https://doi.org/10.1007/s00259-001-0743-8